A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma by unknown
RESEARCH ARTICLE Open Access
A retrospective paired study: efficacy and
toxicity of nimotuzumab versus cisplatin
concurrent with radiotherapy in
nasopharyngeal carcinoma
H. M. Li1, P. Li1, Y. J. Qian1,2, X. Wu1, L. Xie1, F. Wang1, H. Zhang1 and L. Liu3*
Abstract
Background: To compare efficacy and toxicity of nimotuzumab versus cisplatin (CDDP) concurrent with intensity
modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC).
Methods: We retrospectively reviewed patients with NPC from September 2008 to November 2013. The
synchronous regimens included h-R3/RT (nimotuzumab and radiotherapy) one time per week for 6–8 weeks and
CDDP/RT (cisplatin and radiotherapy) every three weeks for 2–3 cycles. All patients in our analysis completed the
planned IMRT and received TPF (docetaxel + cisplatin + 5-fluorouracil) neoadjuvant chemotherapy for two cycles.
Results: Among the 302 NPC patients who were treated definitively with TPF neoadjuvant chemotherapy followed
by IMRT concurrent with nimotuzumab or cisplatin at West China Hospital Sichuan University, 52 patients received
h-R3/RT with complete clinical and follow-up data. Based on age, sex and tumor stage, 104 eligible patients were
propensity-matched, with 52 patients in each treatment group (h-R3/RT and CDDP/RT). With a median follow-up of
50 months, the 5-year overall survival (OS) and progression-free survival (PFS) rates for the h-R3/RT vs. CDDP/RT
treatment groups were 63.9% vs. 81.4% (p = 0.024) and 58.0% vs. 80.6% (p = 0.028), respectively. The h-R3/RT
patients experienced less leukopenia and milder nausea and vomiting. In our sub-analysis, for stage II patients, no
significant differences were found in OS and PFS, whereas milder nausea and vomiting were found in the h-R3/RT
group (p = 0.046). Moreover, for patients older than 60 years, there were no statistically significant differences in OS
and PFS, whereas milder nausea and vomiting was observed in the h-R3/RT group (p = 0.020).
Conclusions: Although CDDP/RT remains the preferred choice for most patients with NPC, h-R3/RT may be a
treatment option for the patients with stage II, older than sixty years old, and who are intolerable to cisplatin.
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Background
Nasopharyngeal carcinoma (NPC) is endemic in Southern
China with an annual incidence of 25 cases per 100,000
[1]. A total of 95% of NPC cases are non-keratinizing
(differentiated and undifferentiated included). It has been
widely known that NPC is closely associated with EB viral
infection, and its pathogeny includes environmental fac-
tors and genetic susceptibility [2]. Radiotherapy comprises
the foundational treatment for nasopharyngeal cancer. In
1998, Al-Sarraf M et al. reported the results of INT 0099
(a phase III clinical trial), making concurrent chemoradio-
therapy (CCRT) as the standard treatment for locally
advanced nasopharyngeal cancer [3]. The National Com-
prehensive Cancer Network (NCCN) has recommended
concurrent chemoradiotherapy with or without adjuvant
chemotherapy for NPC patients with stage II–IV accord-
ing to several prospective randomized trials [4–7].
Radiotherapy induced mucositis and weight loss,
which cause the physical deterioration of patients. Oral
mucositis is sustained for 2–3 weeks after radiotherapy,
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which results in the reduction of tolerance and compli-
ance with adjuvant chemotherapy and which is associated
with poor efficacy of treatment [8]. These facts have grad-
ually made the regimen of concurrent chemoradiotherapy
plus adjuvant chemotherapy undesirable. Theoretically,
conventional concurrent chemotherapy can improve the
local control rate, but its role for eliminating subclinical
metastases is very limited in clinical practice. Clinically,
neoadjuvant chemotherapy can improve the efficacy and
reduce the rate of distant metastasis [9], thus it has been
universally applied of neoadjuvant chemotherapy plus
concurrent chemoradiotherapy for locally advanced
nasopharyngeal carcinoma. Increasing amounts of data
from randomized clinical trials have recommended
cisplatin as the drug for use in concurrent chemoradio-
therapy [10, 11]. However, despite the increasing of
beneficial antitumor effects, cisplatin concurrent with
radiotherapy also elevates the occurrence of severe
toxicities, which include marrow suppression, nausea
and vomiting, which commonly are intolerable to most
patients with nasopharyngeal carcinoma [12]. There-
fore, it is urgent to explore more effective and tolerable
regimens for NPC.
Over-expression of epidermal growth factor receptor
(EGFR) gene amplifications is associated with many
types of cancers, including NPC [13], and the positive-
expression rate of EGFR is more than 90% in non-
keratinizing NPC [14, 15]. Altered EGFR signaling is
widely implicated in cell apoptosis resistance, prolifera-
tion, radiotherapy resistance, metastasis and invasion
[16, 17]. Targeted therapies for treatment of NPC have
become a topic of increased research interest inter-
nationally due to favorable efficacy and low toxicity.
Nimotuzumab is a humanized anti-EGFR mouse mono-
clonal antibody designed to reduce immunoreactivity
and to enhance radio sensitivity [18]. Earlier clinical tri-
als of nimotuzumab concurrent with radiotherapy in
patients with locally advanced head and neck squamous
cell carcinoma reported that this combination therapy
was well tolerated and may enhance the radio curability
of unresectable head and neck neoplasms [19]. A multi-
center, randomized controlled phase II clinical study was
performed to observe the efficacy and adverse reactions of
nimotuzumab combined with radiotherapy for advanced
nasopharyngeal carcinoma, led by the Chinese Academy
of Medical Sciences. The results showed that the 3-year
overall survival of the group treated with nimotuzumab
combined with radiotherapy was 84.29%, significantly
higher than the group treated with radiotherapy alone
(77.61%) [20], which suggested a synergistic effect between
nimotuzumab and radiotherapy. Its side effects were mild,
and it did not affect the normal execution of radiotherapy.
Moreover, nimotuzumab combined with radiotherapy was
recommended in the 2010 version of the Chinese head
and neck cancer practice guidelines. However, the effi-
cacy and toxicity of nimotuzumab concurrent with
radiotherapy compared with cisplatin concurrent with
radiotherapy for the treatment of patients with NPC
remains an area of uncertainty.
In this study, we aimed to shed light on this issue. The
primary endpoint was the evaluation of overall survival
and progression-free survival. Secondary endpoints in-
cluded the assessment of toxicity, including hematological
toxicity, liver function, dermatitis, rash, mucositis, taste
change, vomiting, and weight loss.
Methods
From September 2008 to November 2013, 302 patients
with NPC treated definitively with nimotuzumab or
cisplatin concurrent with IMRT at West China Hospital,
Sichuan University were included. The main study end-
point was efficacy (OS, PFS), and the secondary endpoints
were toxicities.
Patients
A retrospective review was conducted using the case
records of patients with NPC treated at West China
Hospital Sichuan University from September 2008 to
November 2013. Our research retrospectively analyzed
the clinical routine data, and was granted an exemption
from requiring ethics approval by the Subcommittee on
Biomedical Ethics of West China Hospital, Sichuan
University. Patients were eligible for this study if they
met the following inclusion criteria: patients with NPC
were pathologically confirmed at West China Hospital,
the patients did not receive any antitumor therapy be-
fore admission, the intensity modulated radiation ther-
apy (IMRT) was administered at West China Hospital,
all patients received TPF neoadjuvant chemotherapy two
cycles before radiotherapy, synchronous regimens in-
cluded h-R3/RT (nimotuzumab and radiotherapy) and
CDDP/RT (cisplatin and radiotherapy), and the patient’s
ECOG score was less than or equal to 2 points. The
another reason why patients selected to receive nimotu-
zumab rather than cisplatin was that they could not
tolerate the side effects (nausea and vomiting) caused by
neoadjuvant chemotherapy. Before treatment, doctors
introduced the evidence-based medicinal benefits and side
effects of nimotuzumab, and all patients signed informed
consent. Among the 302 patients, there were 52 cases with
complete clinical and follow-up data and 7 cases without
complete clinical and follow-up data in the h-R3/RT group,
and there were 221 cases with complete clinical and
follow-up data and 22 cases without complete clinical and
follow-up data in CDDP/RT group. Due to the significant
differences in general information, we included 52 pairs
based on age, sex and tumor stage (2010 7th edition AJCC
staging classification) [21]. We selected the individual
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CDDP/RT patients paired with 52 h-R3/RT patients with
complete clinical and follow-up data one by one, according
to the following conditions: first, the age difference within
the pair was less than 5 years; second, tumor stage, depth
of invasion (T), lymph node metastasis (N), distant metas-
tasis (M), clinical stages were consistent in the h-R3/RT
patients as much as possible; third, the difference between
the number of men and women was not more than 10;
and finally, nonparametric tests were used to ensure that
there was no difference in paired factors.
Treatment
Neoadjuvant chemotherapy
Eligible patients received two cycles TPF neoadjuvant
chemotherapy (docetaxel 75 mg/m2 d1 +DDP 25 mg/m2
d1-3 + 5-fu 600 mg/m2 d1-5). The schedule, dosage and
duration were similar to Kong Lin’s study [22]. Radiotherapy
started three weeks after the two neoadjuvant cycles.
Radiation therapy
The radioactive source was a medical linear accelerator
(6 MV X). All patients received intensity modulated
radiotherapy (IMRT) with a 2.12 or 2.24 Gy (skull base
bone destruction) fraction once a day for 5 days per week
up to a total of 70 or 74 Gy (skull base bone destruction)
in 33 fractions. The delineation of target volumes was
based on imaging (CT, MRI or FDG- PET), and the target
volumes were performed in the same series. The tech-
nique and dose of radiotherapy was consistent with the
principles of the NCCN guidelines.
Synchronous regimens
Nimotuzumab (200 mg) was administered once weekly
for 6–8 weeks, and cisplatin (25 mg/m2) was administered
every three weeks (d1-3) for 2–3 cycles according to the
NCCN guidelines. The 200 mg dose of nimotuzumab was
selected because this dose was reported to be as effective
as 400 mg [19, 23]. Nimotuzumab or cisplatin were
administered concurrent with IMRT.
Antiemetic
We selectively used antiemetic therapy to reduce gastro-
intestinal reactions depending on the severity of nausea and
vomiting in patients of the two groups. Because the details
of antiemetic use had been lost, it was impossible to calcu-
late the relevant statistics. The antiemetic administered in
our study included 5-HT3 antagonist (ondansetron/grani
setron/tropisetron), a dopamine receptor antagonist (meto
clopramide), an H1 receptor antagonist (diphenhydramine),
and a proton pump inhibitor (pantoprazole).
Follow-up
Via telephone or outpatient clinic visit, we recorded
survival, recurrence and metastasis, and side effects,
including hematological toxicities, liver function, derma-
titis, rash, mucositis, altered taste, nausea and vomiting,
weight loss and so on. Hematologic toxicity mainly com-
prised bone marrow suppression, including leukopenia,
anemia and thrombocytopenia. Abnormal liver function
was mainly manifested by elevated liver enzymes. Blood
routine, biochemical routine and other toxicities were
estimated at least once a week. Side effects were evalu-
ated according to the CTCAE (Common Terminology
Criteria for Adverse Events) 4.0 criteria.
After completion of treatments, the patients were sub-
sequently reexamined every three months for two years,
then every six months for the next three years, and
annually thereafter to assess tumor status. The reexami-
nations included assessments of blood toxicity, EB virus
DNA, pharyngorhinoscopy and biopsy, nasopharynx and
neck MRI, chest CT, abdominal ultrasound and bone
EC, etc. The follow-up time was calculated from the date
of diagnosis of nasopharyngeal carcinoma to the date of
death or last follow-up time.
Statistical analysis
All statistical analyses were performed using IBM SPSS
20.0 software, and the tests were considered significant
at p ≤ 0.05. The Kaplan–Meier method was used to esti-
mate the 95% confidence intervals (95% CIs) of overall
survival and progression-free survival. Overall survival
was calculated from the date of diagnosis to the date of
death from any cause or the last scheduled visit.
Progression-free survival was defined as the time from
diagnosis to the time of tumor progression or the last
scheduled visit. Survival distributions were compared
using a log-rank test. Toxicities were estimated by a
paired rank sum test. Univariate analysis was performed
using COX regression. Multivariate analysis using the
COX proportional hazards model was used to calculate
the hazard ratio (HR) with 95% CIs and to adjust for
independent potential prognostic factors. The following
potentially prognostic factors were considered in the
multivariate analysis according to the results of univari-
ate analysis and those mentioned in previous studies:
age, sex, T stage, N stage, AJCC stage, anemia, derma-
titis, nausea and vomiting, weight loss and drug. Assign-
ment expressions of the factors in this research are listed
in Additional file 1: Table S4.
Results
Patient characteristics
The patients and tumor characteristics of 104 cases are
summarized in Table 1,and the general information of
total 302 cases was listed in Additional file 1: Table S7.
One hundred and four eligible patients were propensity-
matched, with 52 patients in each group, and the median
follow-up time was 50 months (range 12–74 months).
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Pathological type of the patients was non-keratinizing.
All patients received the entire treatment IMRT course
with the prescribed dose and two cycles of TPF neoadju-
vant chemotherapy, and none of them underwent
adjuvant chemotherapy after radiotherapy. A total of 46
(88.5%) and 6 patients (11.5%) in h-R3/RT group
received 8 and 6 doses of nimotuzumab, respectively.
And a total of 44 (84.6%) and 8 patients (15.4%) in
CDDP/RT group received 3 and 2 cycles of cisplatin, re-
spectively. Patient compliance is reported in Additional
file 1: Table S5. According to the 2010 AJCC staging
classification (7th edition) for nasopharyngeal cancer
[21], patients in our study were divided into stage II (26
patients; 25.0%), III (41 patients; 39.4%) and non-metastatic
stage IV (37 patients; 35.6%). There were no significant
differences among the following variables: age (<60 vs. ≥
60), sex, T stage, N stage, AJCC stage and ECOG scores (all
p values > 0.05).
Efficacy
At a median follow-up of 50 months (range 12–74
months) for living patients, the 5-year OS and PFS rates
of h-R3/RT and CDDP/RT group were 63.9% vs. 81.4%
(p = 0.024) and 58.0% vs. 80.6% (p = 0.028), respectively.
The survival curves were shown in Fig. 1.
Among the NPC patients with stage II AJCC, the OS
of the two groups were not significantly different (p =
0.571). Furthermore, for the patients aged 60 years or
older, there were no significant differences in OS (p =
0.236). The survival curves are shown in Additional
file 2: Figures S1 and S2.
Toxicity
The treatment toxicities resulting from the synchronous
drugs were generally mild, and no fatal toxicity reaction
occurred among all patients. Leukopenia was the most
common hematological toxicity, and it was not accom-
panied by any serious infections. It was rare to find a
specific toxicity that was induced by nimotuzumab,
while it was common to suffer from nausea and vomit-
ing in patients who received cisplatin.
Using paired rank sum test, we found significant dif-
ferences in toxicities between two groups: leukopenia,
nausea and vomiting. Patients in the h-R3/RT group ex-
perienced less leukopenia, and milder nausea and vomit-
ing with p values of 0.048 and 0.000, respectively
(Table 2). Oral mucositis was one of the most common
RT-related toxicities, grade 3 or 4 oral mucositis as
observed in 25 (48.1%) and 30 (57.7%) patients in the
CDDP/RT and h-R3/RT groups, respectively. While
grade 3 or 4 dermatitis was observed in 1 (1.9%) and 2
(3.8%) patients in the CDDP/RT and h-R3/RT groups,
respectively. In total, 47 (90.4%) and 46 (88.5%) patients
experienced taste change the CDDP/RT and h-R3/RT
groups, respectively. Most patients in our study experi-
enced weight loss, and grade 3 or 4 weight loss was ob-
served in 15 (28.8%) and 13(25.0%) patients in the
CDDP/RT and h-R3/RT groups, respectively. In our
study, no patients required RT interruptions or termina-
tions because of acute toxicity. Then, we analyzed toxic-
ities among patients in stage II AJCC and found milder
nausea and vomiting in the h-R3/RT group (p = 0.046)
(Table 3). Moreover, as depicted in Table 4, among pa-
tients older than 60 years, a significant difference was
also found in some toxicities, as patients in the h-R3/RT
group experienced milder nausea and vomiting (p =
0.020).
Table 1 Patients and tumor characteristics of the h-R3/RT and
CDDP/RT groups (N = 104)
h-R3/RT (N = 52) CDDP/RT (N = 52)
Characteristics [n (%)] [n (%)] P Value*
Age 1.000
< 60 45 (86.5%) 45 (86.5%)
≧60 7 (13.5%) 7 (13.5%)
Sex 0.083
Male 42 (82.7%) 36 (69.2%)
Female 10 (17.3%) 16 (30.8%)
T category 0.799
1 11 (21.2%) 11 (21.2%)
2 13 (25.0%) 14 (26.9%)
3 12 (23.1%) 12 (23.1%)
4 16 (30.7%) 15 (28.8%)
N category 0.957
0 3 (5.8%) 4 (7.7%)
1 20 (38.4%) 19 (36.5%)
2 23 (44.3%) 23 (44.3%)
3 6 (11.5%) 6 (11.5%)
M category 1.000
0 52 (100%) 52 (100%)
1 0 (0.00%) 0 (0.00%)
Clinical stage 0.831
II 13 (25.0%) 13 (25.0%)
III 20 (38.5 0%) 21 (40.4%)
IV (non-metastatic) 19 (36.5.0%) 18 (34.6%)
Histologic type
non-keratinizing 52 (100%) 52 (100%)
Total RT (70/74)a (70/74)a
dose (Gy)
ECOG 0-2 0-2
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/
RT cisplatin and radiotherapy. ECOG Eastern Cooperative Oncology Group
aa total of 74 Gy when patients had skull base bone destruction
*All p values were obtained by the non-parametric test
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Patterns of relapse and metastasis
The patterns of treatment failure and causes of death are
summarized in Table 5. At the median follow-up of
50 months, there were 19 deaths. At the time of the ana-
lysis, two patient had locoregional failure, two patient
showed locoregional failure and distant metastases, and
ten patients developed distant metastases.
Prognosis
The overall survival (OS) of 104 cases were analyzed by
univariate and multivariable COX, which were listed in
Additional file 1: Table S1 and Additional file 1: Table S2,
respectively. Based on results of previously reported stud-
ies and on the results of the univariate analysis, we
included sex, age, T category, N category, clinical stage
and side effects in the COX analysis. The results of univar-
iate COX analysis showed that T category, N category,
clinical stage, vomiting and drug were prognostic fac-
tors for nasopharyngeal carcinoma (Additional file 1:
Table S1). Furthermore, age, N category and vomiting
were indicated as independent prognostic factors for
nasopharyngeal carcinoma according to the multivari-
able COX analysis. (Additional file 1: Table S2).
Discussion
This study is a retrospective analysis of our institution’s
history of treating nasopharyngeal carcinoma with h-R3/
RT compared to radiotherapy and platinum-based chemo-
therapy (CDDP/RT). We followed up 104 patients, and at
the median of 50 months, the 5-year OS and PFS rates
were 63.9% vs. 81.4% (p = 0.024) and 58.0% vs. 80.6% (p =
0.028), respectively. CDDP/RT achieved better survival,
while the patients who received h-R3/RT experienced less
toxicity. It was suggested that, in patients who were
greater than 60 years of age with stage II, there was no sig-
nificant difference in survival, while h-R3/RT patients ex-
hibited lower side effects.
To the best of our knowledge, this study is the first
study that compared the efficacy and toxicities of nimo-
tuzumab versus cisplatin concurrent with IMRT in
nasopharyngeal carcinoma patients. In our study, the 5-
year OS and PFS rates were 63.9% vs. 81.4% (p = 0.024)
and 58.0% vs. 80.6% (p = 0.028), respectively. Al-Sarraf
M et al. reported that the 3-year survival rate for
patients who received CDDP/RT was 78% [3]. The dif-
ference in the survival rate may be caused by different
radiotherapy techniques. Our study used IMRT, which is
a more advanced radiotherapy technique. In a phase II
clinical study, the long-term follow-up results failed to
show a significant difference between h-R3/RT and radio-
therapy alone in the long-term metastasis rate and sur-
vival rate [24]. The 3-year OS rates of the two groups
dropped to 94.4 and 88.2%, respectively (p = 0.518). Thus,
the strength of nimotuzumab combined with radiotherapy
in NPC may be still largely due to a strengthening of the
radiation antitumor effect.
Our study also found significant differences in toxic-
ities between the h-R3/RT and CDDP/RT group. More
leukopenia and heavier nausea and vomiting emerged in
the CDDP/RT group, which might result from cisplatin-
induced inherent hematologic toxicities and heavier
gastrointestinal reactions [25].
Anti-EGFR-targeted therapy has become an important
aspect of cancer treatment in recent years. Compared
with other EGFR inhibitors, nimotuzumab shows a
greater advantage in terms of less toxicity. For example,
the toxicities of cetuximab include acne-like skin rash,
itching, fever, nausea and so on [26]. With its humanized
degree over 90%, nimotuzumab remarkably reduces hu-
man anti-mouse antibody and allergic reactions. Consist-
ently, in our study, there were only three patients who
suffered from acne-like skin rash in the h-R3/RT group.
In the CDDP/RT group, mild rash occurred in two
patients, which was caused by mild allergic reactions. A
previous study showed that patients with locoregionally
advanced nasopharyngeal carcinoma had good tolerance
for h-R3/RT [27]. In our study, h-R3/RT did not aggra-
vate the acute radiation reactions.
For sub-analyses, we analyzed the survivals of stage II
patients in the h-R3/RT and CDDP/RT groups and
Fig. 1 Overall survival (a) and progression-free survival (b) of patients who received h-R3/RT (N = 52) and CDDP/RT (N = 52) treatment
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found no significant difference in OS and PFS rates,
likely suggesting that local control of the disease is
mainly conveyed by radiation, without any correlation
with the synchronous drugs [28]. Similar to the results
above, stage II patients in the h-R3/RT group experi-
enced less toxic effects. Moreover, among the patients
aged more than 60 years, there was no significant differ-
ence in survival between the h-R3/RT and CDDP/RT
groups, and less toxic effects were found in the h-R3/RT
Table 2 Toxicities of the h-R3/RT and CDDP/RT groups (N = 104)
Toxicities
(RTOG Grade)
h-R3/RT (N = 52)
[n (%)]




(1&2) 32 (61.5%) 32 (61.5%)
(3&4) 1 (1.9%) 7 (13.5%)
PLT 0.752
(1&2) 19 (36.5%) 18 (34.6%)
(3&4) 1 (1.9%) 2 (3.8%)
HB 0.499
(1&2) 27 (51.9%) 26 (50%)
(3&4) 0 (0.00%) 0 (0.00%)
ALT 0.294
(1&2) 10 (19.1%) 8 (11.9%)
(3&4) 0 (0.00%) 0 (0.00%)
AST 0.197
(1&2) 10 (19.2%) 5 (9.6%)
(3&4) 0 (0.00%) 0 (0.00%)
GGT 0.166
(1&2) 9 (17.3%) 5 (9.6%)
(3&4) 0 (0.00%) 0 (0.00%)
Dermatitis 0.445
(1&2) 33 (63.5%) 44 (84.6%)
(3&4) 2 (3.8%) 1 (1.9%)
Rash 0.248
(1&2) 5 (9.6%) 3 (5.8%)
(3&4) 1 (1.9%) 0 (0.00%)
Mucositis 0.093
(1&2) 21 (40.4%) 26 (50%)
(3&4) 30 (57.7%) 25 (48.1%)
Taste change 0.763
yes 46 (88.5%) 47 (90.4%)
no 6 (11.5%) 5 (9.6%)
Vomit 0.000*
only nausea 12 (23.1%) 2 (3.8%)
nausea and vomit 5 (9.6%) 43 (78.8%)
Weight loss 0.249
(1&2) 26 (50.0%) 30 (57.7%)
(3&4) 13 (25.0%) 15 (28.8%)
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/
RT cisplatin and radiotherapy. WBC white blood cell, PLT Platelets, HB
hemoglobin, ALT alanine transaminase, AST glutamic-oxalacetic transaminease,
GGT gamma glutamyl transpeptidase
*All p values were obtained by the paired rank sum test
Table 3 Toxicities in stage II patients who received h-R3/RT or
CDDP/RT (N = 26)
Toxicities (RTOG Grade) h-R3/RT (N = 13)
[n (%)]




(1&2) 10 (76.9%) 6 (46.2%)
(3&4) 0 (0.0%) 3 (23.1%)
PLT 0.380
(1&2) 6 (46.2%) 6 (46.2%)
(3&4) 0 (0.00%) 1 (7.7%)
HB 0.083
(1&2) 8 (61.5%) 5 (61.5%)
(3&4) 0 (0.0%) 0 (0.0%)
ALT 0.655
(1&2) 2 (15.4%) 3 (23.1%)
(3&4) 0 (0.0%) 0 (0.0%)
AST 0.157
(1&2) 2 (15.4%) 0 (0.0%)
(3&4) 0 (0.0%) 0 (0.0%)
GGT 1.000
(1&2) 1 (7.7%) 1 (7.7%)
(3&4) 0 (0.0%) 0 (0.0%)
Dermatitis 0.414
(1&2) 8 (61.5%) 11 (84.6%)
(3&4) 0 (0.0%) 0 (0.0%)
Rash 0.655
(1&2) 3 (23.1%) 2 (15.4%)
(3&4) 0 (0.0%) 0 (0.0%)
Mucositis 0.093
(1&2) 5 (38.5%) 8 (61.5%)
(3&4) 7 (53.8%) 5 (38.5%)
Taste change 1.000
yes 13 (100%) 13 (100%)
no 0 (0.0%) 0 (0.0%)
Vomit 0.046*
only nausea 6 (46.2%) 3 (23.1%)
Nausea and vomit 2 (15.4%) 10 (76.9%)
Weight loss 0.305
(1&2) 8 (61.6%) 7 (53.8%)
(3&4) 3 (23.1%) 5 (38.5%)
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/
RT cisplatin and radiotherapy
*All p values were obtained using the paired rank sum test
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group. Therefore, we can reasonably believe that h-R3/
RT is a better choice for stage II patients and patients
aged more than 60 years. Previous studies of head and
neck carcinomas and nasopharyngeal carcinoma have
indicated that concurrent chemoradiotherapy is more
effective than radiotherapy alone. However, there were
no patients who received radiotherapy alone in our
study, and thus we cannot compare the differences be-
tween concurrent chemoradiotherapy and radiotherapy
alone. It was previously reported that the 5-year OS rate
of stage II nasopharyngeal carcinoma patients treated with
concurrent chemoradiotherapy compared to radiotherapy
alone was 94.5% vs. 85.8%, respectively [29]. Concurrent
chemoradiotherapy is feasible and effective in elderly
patients with locoregionally advanced NPC who are not
troubled with any severe comorbidities [30, 31]. Conclu-
sively, our results suggested h-R3/RT as a alternative regi-
men, which not only guaranteed efficacy but also reduced
side effects. Owing to our retrospective study and its rela-
tively small sample size, this treatment provides only a
potential remedy for concurrent radiotherapy of NPC in
some specific patients.
The main prognostic factors are age, gender, clinical
stage (T, N category included); the survival rate has been
shown to decrease with the increasing T category and N
category patients [32]. According to our data, T category,
N category, clinical stage, vomit and synchronous drug
were suspected to affect patients’ survivals according to
the univariate COX analysis. The multivariate COX
analysis indicated age, N category, and vomiting as inde-
pendent prognostic factors. In contrast, gender was not
significant in the analyses, which might have been a con-
sequence of the small sample size and an underpowered
analysis. Then, we analyzed the data of 302 patients
using the methods mentioned above, and found that gen-
der is a prognostic factor of nasopharyngeal carcinoma
(Additional file 1: Table S8 and Additional file 1: Table S9).
We observed that the synchronization of different drugs
induced different outcomes: better survival was observed
for the CDDP/RT group, which may be associated with the
cytotoxicity of cisplatin. Moreover, h-R3/RT in nasopha-
ryngeal carcinoma was may not improve long-term
survival [3, 24]. Local recurrence and distant metastasis
result in failed nasopharyngeal carcinoma treatment [33].
Moreover, we also analysised At the median follow-up of
50 months in our study, two patient had locoregional fail-
ure, two patient showed locoregional failure and distant
Table 4 Toxicities in patients aged more than 60 years who
received h-R3/RT or CDDP/RT. (N = 14)
Toxicities (RTOG Grade) h-R3/RT (N = 7)
[n (%)]




(1&2) 3 (42.9%) 5 (71.4%)
(3&4) 0 (0.00%) 0 (0.00%)
PLT 0.059
(1&2) 5 (71.4%) 1 (14.3%)
(3&4) 0 (0.00%) 0 (0.00%)
HB 0.157
(1&2) 2 (28.6%) 5 (71.4%)
(3&4) 0 (0.00%) 0 (0.00%)
ALT 0.317
(1&2) 0 (0.00%) 1 (14.3%)
(3&4) 0 (0.00%) 0 (0.00%)
AST 0.317
(1&2) 0 (0.00%) 1 (14.3%)
(3&4) 0 (0.00%) 0 (0.00%)
GGT 1.000
(1&2) 0 (0.00%) 0 (0.00%)
(3&4) 0 (0.00%) 0 (0.00%)
Dermatitis 0.317
(1&2) 4 (57.1%) 7 (100%)
(3&4) 0 (0.00%) 0 (0.00%)
Rash 1.000
(1&2) 0 (0.00%) 0 (0.00%)
(3&4) 0 (0.00%) 0 (0.00%)
Mucositis 0.891
(1&2) 2 (28.6%) 3 (42.9%)
(3&4) 4 (57.1%) 2 (52.4%)
Taste change 1.000
yes 5 (71.4%) 6 (85.7%)
no 2 (28.6%) 1 (14.3%)
Vomit 0.020
only nausea 0 (0.00%) 1 (2.4%)
Nausea and vomit 0 (0.00%) 5 (71.4%)
Weight loss 0.174
(1&2) 2 (28.6%) 4 (57.1%)
(3&4) 1 (14.3%) 2 (26.2%)
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/
RT cisplatin and radiotherapy
* All p values were obtained by use of the paired rank sum test
Table 5 Patterns of relapse of all patients who received h-R3/RT
or CDDP/RT. (N = 104)
h-R3/RT (N = 52) CDDP/RT (N = 52)
Relapse and metastasis [n (%)] [n (%)]
Local recurrence 2 (3.9%) 2 (3.9%)
Hepatic metastases 2 (3.9%) 3 (5.8%)
Lung metastasis 1 (1.9%) 3 (5.8%)
Bone metastasis 1 (1.9%) 2 (3.9%)
Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/
RT cisplatin and radiotherapy
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metastases, and ten patients developed distant metastases.
The sites of recurrence were mainly bone, lung and liver,
consistent with previous reports in the literature [34].
It is worth mentioning that role of neoadjuvant
chemotherapy has been questioned and evaluated in
many ways [35, 36]. Most of the proponent opinions on
neoadjuvant chemotherapy were based on the patients
with stages III or IV. The cases in this study included
patients with stages II, III and IV from September 2008
to November 2013 at West China Hospital Sichuan
University. During the period of follow-up time, neoad-
juvant chemotherapy (category 3) was recommended for
patients with stage II by NCCN guidelines of Head and
Neck Cancers (Additional file 1: Table S6). Furthermore,
we analyzed the patients with stages III-IV. CDDP/RT
patients achieved better survival (p = 0.009), while h-R3/
RT patients experienced less leukopenia and milder
nausea and vomiting, the p values were respectively 0.022
and 0.000 (Additional file 2: Figure S3, Additional file 1:
Table S3). The results are similar to that obtained from
104 patients with stages II, III or IV. Although the role of
neoadjuvant chemotherapy has been controversial ac-
cording to recent literatures, it still remains to be
explored. Our results, to some extent, provided dir-
ection for the therapeutic strategy of nasopharyngeal
carcinoma. Meanwhile, we are expecting more
powerful results about neoadjuvant chemotherapy,
which may have a greater research value and appli-
cation prospect in the future.
The results presented here must be interpreted cau-
tiously because of the retrospective nature of this study
and the small sample size. First, numerous factors are
considered when determining the type of synchronous
drugs for patients, most of which could not be captured
in a retrospective medical record review, such as the
economic condition of the patients. Second, as in many
retrospective analyses, missing data were common. We
may not have accounted for some confounding factors.
Finally, some patients might have chosen other treat-
ments, such as cell therapy, Chinese medicine treatment
or other non-chemotherapy-based clinical trials, which
could have limited the generalizability of these results.
Owing to our retrospective study and its relatively small
sample size, some prospective, randomized, well-
designed, and large sample clinical studies are warranted
to confirm these indications.
Conclusions
Our findings suggest that concurrent administration of
h-R3/RT might be a selectable strategy against nasopha-
ryngeal carcinoma, although CDDP/RT remained the
preferred choice for most patients with nasopharyngeal
carcinoma. The regimen of h-R3/RT may be considered
less toxic for patients with nasopharyngeal carcinoma,
especially for some patients who do not well tolerate
cisplatin, patients with stage II NPC and older patients.
More effective and tolerable treatment regimens should
be explored to improve survival rates and reduce the
side-effects of patients with nasopharyngeal carcinoma.
We are looking forward to prospective, well-designed,
and large sample clinical studies.
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